Best Known For
Xofluza is a first-in-class cap-dependent endonuclease inhibitor
Core Claims
- Xofluza is typically prescribed as a single oral dose
- It is used for the treatment of acute uncomplicated influenza
- It is also used for preventive treatment after exposure
- Xofluza is manufactured by Shionogi Inc.
- It works by inhibiting the viral endonuclease enzyme essential for viral gene transcription
Differentiators
- It is a first-in-class cap-dependent endonuclease inhibitor
- It is used after symptoms for no more than 48 hours
- It is approved for treatment for ages 12 years and older
- It is indicated for preventive treatment following close contact
Pricing Perception:
Not Mentioned